1
|
Schnyder JL, de Jong HK, Bache BE, Schaumburg F, Grobusch MP. Long-term immunity following yellow fever vaccination: a systematic review and meta-analysis. Lancet Glob Health 2024; 12:e445-e456. [PMID: 38272044 DOI: 10.1016/s2214-109x(23)00556-9] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2023] [Revised: 11/20/2023] [Accepted: 11/24/2023] [Indexed: 01/27/2024]
Abstract
BACKGROUND Long-term immunity following yellow fever vaccination remains controversial. We aimed to summarise the literature regarding the long-term protection (≥10 years) conveyed by a single dose of yellow fever vaccination. METHODS In this systematic review and meta-analysis, we searched 11 databases from database inception to Aug 24, 2023. We included cohort and cross-sectional studies reporting immunogenicity outcomes for children or adults who received a single dose of yellow fever vaccination 10 or more years ago. Case series and single case reports were excluded. Participants who received more than one dose of yellow fever vaccination before measurement of the outcome were excluded. Identified records were reviewed by two independent reviewers. The primary outcome of the meta-analysis was the pooled seroprotection rate. Risk of bias was assessed with the Risk Of Bias In Non-randomized Studies of Interventions tool, and the Joanna Briggs Institute tool for analytical cross-sectional studies. Studies of moderate or good quality that reported seroprotection were included for random-effects meta-analysis and stratified by endemicity and specific risk groups. The study was registered with PROSPERO, CRD42023384087. FINDINGS Of the 7363 articles identified by our search, 39 were eligible for inclusion for systematic review. These studies comprised 2895 individuals vaccinated 10-60 years ago. 20 studies were included in the meta-analysis. Pooled seroprotection rates were 94% (95% CI 86-99) among healthy adults in a non-endemic setting (mostly travellers) and 76% (65-85) in an endemic setting (all Brazilian studies). The pooled seroprotection rate was 47% (35-60) in children (aged 9-23 months at time of vaccination) and 61% (38-82) in people living with HIV. Reported criteria for seroprotection were highly heterogeneous. INTERPRETATION The gathered evidence suggests that a single dose of yellow fever vaccination provides lifelong protection in travellers. However, in people living with HIV and children (younger than 2 years), booster doses might still be required because lower proportions of vaccinees were seroprotected 10 or more years post-vaccination. Lower observed seroprotection rates among residents of endemic areas were partly explained by the use of a higher cutoff for seroprotection that was applied in Brazil. Studies from sub-Saharan Africa were scarce and of low quality; thus no conclusions could be drawn for this region. FUNDING None.
Collapse
Affiliation(s)
- Jenny L Schnyder
- Center for Tropical Medicine and Travel Medicine, Department of Infectious Diseases, Division of Internal Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands
| | - Hanna K de Jong
- Center for Tropical Medicine and Travel Medicine, Department of Infectious Diseases, Division of Internal Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands
| | - Bache E Bache
- Center for Tropical Medicine and Travel Medicine, Department of Infectious Diseases, Division of Internal Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands; Masanga Medical Research Unit, Masanga, Sierra Leone
| | - Frieder Schaumburg
- Masanga Medical Research Unit, Masanga, Sierra Leone; Institute of Medical Microbiology, University Hospital Münster, Münster, Germany
| | - Martin P Grobusch
- Center for Tropical Medicine and Travel Medicine, Department of Infectious Diseases, Division of Internal Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands; Masanga Medical Research Unit, Masanga, Sierra Leone; Institute of Tropical Medicine, German Centre for Infection Research, University of Tübingen, Tübingen, Germany; Centre de Recherches Médicales en Lambaréné, Lambaréné, Gabon; Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
| |
Collapse
|
2
|
Advances in Next-Generation Coronavirus Vaccines in Response to Future Virus Evolution. Vaccines (Basel) 2022; 10:vaccines10122035. [PMID: 36560445 PMCID: PMC9785936 DOI: 10.3390/vaccines10122035] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2022] [Revised: 11/23/2022] [Accepted: 11/25/2022] [Indexed: 12/03/2022] Open
Abstract
Coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread to more than 230 countries and territories worldwide since its outbreak in late 2019. In less than three years, infection by SARS-CoV-2 has resulted in over 600 million cases of COVID-19 and over 6.4 million deaths. Vaccines have been developed with unimaginable speed, and 11 have already been approved by the World Health Organization and given Emergency Use Listing. The administration of several first-generation SARS-CoV-2 vaccines has successfully decelerated the spread of COVID-19 but not stopped it completely. In the ongoing fight against viruses, genetic mutations frequently occur in the viral genome, resulting in a decrease in vaccine-induced antibody neutralization and widespread breakthrough infection. Facing the evolution and uncertainty of SARS-CoV-2 in the future, and the possibility of the spillover of other coronaviruses to humans, the need for vaccines with a broad spectrum of antiviral variants against multiple coronaviruses is recognized. It is imperative to develop a universal coronavirus or pan-coronavirus vaccine or drug to combat the ongoing COVID-19 pandemic as well as to prevent the next coronavirus pandemic. In this review, in addition to summarizing the protective effect of approved vaccines, we systematically summarize current work on the development of vaccines aimed at suppressing multiple SARS-CoV-2 variants of concern as well as multiple coronaviruses.
Collapse
|
3
|
Arakpogun EO, Rodrigo P, Olan F. "You Shall Not Pass" without a Jab: An Institutional Theory Perspective to COVID-19 Vaccine Passport Policies. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH 2022; 19:14105. [PMID: 36360982 PMCID: PMC9654031 DOI: 10.3390/ijerph192114105] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 08/22/2022] [Revised: 10/21/2022] [Accepted: 10/27/2022] [Indexed: 06/16/2023]
Abstract
The recent health crises (e.g., COVID-19, Ebola and Monkeypox) have pointed out huge disparities in vaccine accessibility across the world. Nonetheless, certain governments have instituted vaccine passport policies (VPPs) to manage public health, raising mixed concerns from the public. Focusing on COVID-19 outbreak as an example, this review and commentary article utilises an institutional theory perspective to uncover the factors contributing to the global vaccine divide. We also explore the wider impact of VPPs to determine whether such tools promote freedom or social exclusion. Our insights shed light on a controversial and increasingly divisive policy with an international dimension and institutional implications. For instance, while some argue that VPPs may be relatively better than the blunt instrument of lockdowns, VPPs also implicate access and discrimination concerns. Given the various reasons for global vaccine disparities, a hybrid policy that combines vaccine passports with other public health practices (e.g., rapid lateral flow/affordable polymerase chain reaction (PCR) tests and good hygiene) may be more viable. Furthermore, while VPPs may not be desirable and acceptable domestically, they may be inevitable for international travel.
Collapse
|
4
|
Tuells J, Henao-Martínez AF, Franco-Paredes C. The Perennial Threat of Yellow Fever. Arch Med Res 2022; 53:649-657. [DOI: 10.1016/j.arcmed.2022.10.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2022] [Accepted: 10/13/2022] [Indexed: 11/24/2022]
|
5
|
Rosenstein MD, de Visser AW, Visser LG, Roukens AHE. Long-term immunity after a single yellow fever vaccination in travelers vaccinated at 60 years or older: A 10-year follow-up study. J Travel Med 2021; 28:6353012. [PMID: 34401911 PMCID: PMC8715414 DOI: 10.1093/jtm/taab126] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/13/2021] [Revised: 07/21/2021] [Accepted: 08/02/2021] [Indexed: 11/13/2022]
Abstract
BACKGROUND In 2013, the World Health Organization (WHO) revised their position on yellow fever vaccination, in which revaccination every 10 years was no longer required, and that a single-dose provided life-long protection. However, research data on the immunogenicity of YF vaccine in people aged 60 years and over are scarce. Indeed, immunosenescence may result in lower virus neutralizing antibody titers after primary vaccination and a more rapid waning immunity. Therefore, we tested the hypothesis that older travelers, vaccinated at 60 years or older are more likely to become seronegative in comparison to young adults 10 years after primary YF vaccination. METHODS This is a 10-year follow-up study of an earlier prospective controlled cohort study. In the original trial, the neutralizing antibody response was measured in older travelers (aged 60-81 years, N = 28) and young adults (aged 18-28 years, N = 30) up to 28 days after a primary yellow fever vaccination. Ten years later, we collected serum samples of 22/28 (78%) elderly (71-85 years) and 14/30 (47%) controls (29-40 years), and determined their neutralizing antibody titers by plaque reduction neutralization test (PRNT80). Seropositivity was defined as plaque formation reduction of 80% at a serum dilution of 10 or more (PRNT80 ≥ 10). RESULTS All participants (36/36) were still seropositive 10 years after primary vaccination. The geometric mean concentrations were not statistically different between the older and younger participants (6.7 IU/mL vs. 8.6 IU/mL, P = 0.5). CONCLUSIONS All older travelers were seropositive, 10 years after a primary YF vaccination at the age of ≥60 years. These data suggest that in older travelers a single vaccination is sufficient to convey long-lasting immunity for at least 10 years, and is in support the position of the WHO on a single-dose yellow fever vaccination.
Collapse
Affiliation(s)
- Mareen D Rosenstein
- Department of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands
| | - Adriëtte W de Visser
- Department of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands
| | - Leo G Visser
- Department of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands
| | - Anna H E Roukens
- Department of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands
| |
Collapse
|
6
|
Oreshkova N, Myeni SK, Mishra N, Albulescu IC, Dalebout TJ, Snijder EJ, Bredenbeek PJ, Dallmeier K, Kikkert M. A Yellow Fever 17D Virus Replicon-Based Vaccine Platform for Emerging Coronaviruses. Vaccines (Basel) 2021; 9:1492. [PMID: 34960238 PMCID: PMC8704410 DOI: 10.3390/vaccines9121492] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2021] [Revised: 11/15/2021] [Accepted: 12/13/2021] [Indexed: 01/14/2023] Open
Abstract
The tremendous global impact of the current SARS-CoV-2 pandemic, as well as other current and recent outbreaks of (re)emerging viruses, emphasize the need for fast-track development of effective vaccines. Yellow fever virus 17D (YF17D) is a live-attenuated virus vaccine with an impressive efficacy record in humans, and therefore, it is a very attractive platform for the development of novel chimeric vaccines against various pathogens. In the present study, we generated a YF17D-based replicon vaccine platform by replacing the prM and E surface proteins of YF17D with antigenic subdomains from the spike (S) proteins of three different betacoronaviruses: MERS-CoV, SARS-CoV and MHV. The prM and E proteins were provided in trans for the packaging of these RNA replicons into single-round infectious particles capable of expressing coronavirus antigens in infected cells. YF17D replicon particles expressing the S1 regions of the MERS-CoV and SARS-CoV spike proteins were immunogenic in mice and elicited (neutralizing) antibody responses against both the YF17D vector and the coronavirus inserts. Thus, YF17D replicon-based vaccines, and their potential DNA- or mRNA-based derivatives, may constitute a promising and particularly safe vaccine platform for current and future emerging coronaviruses.
Collapse
Affiliation(s)
- Nadia Oreshkova
- Center of Infectious Diseases LU-CID, Department of Medical Microbiology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands; (N.O.); (S.K.M.); (I.C.A.); (T.J.D.); (E.J.S.); (P.J.B.)
| | - Sebenzile K. Myeni
- Center of Infectious Diseases LU-CID, Department of Medical Microbiology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands; (N.O.); (S.K.M.); (I.C.A.); (T.J.D.); (E.J.S.); (P.J.B.)
| | - Niraj Mishra
- Laboratory of Virology and Chemotherapy, Molecular Vaccinology and Vaccine Discovery, Department of Microbiology, Immunology and Transplantation, Rega Institute, KU Leuven, Herestraat 49 Box 1043, 3000 Leuven, Belgium; (N.M.); (K.D.)
| | - Irina C. Albulescu
- Center of Infectious Diseases LU-CID, Department of Medical Microbiology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands; (N.O.); (S.K.M.); (I.C.A.); (T.J.D.); (E.J.S.); (P.J.B.)
| | - Tim J. Dalebout
- Center of Infectious Diseases LU-CID, Department of Medical Microbiology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands; (N.O.); (S.K.M.); (I.C.A.); (T.J.D.); (E.J.S.); (P.J.B.)
| | - Eric J. Snijder
- Center of Infectious Diseases LU-CID, Department of Medical Microbiology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands; (N.O.); (S.K.M.); (I.C.A.); (T.J.D.); (E.J.S.); (P.J.B.)
| | - Peter J. Bredenbeek
- Center of Infectious Diseases LU-CID, Department of Medical Microbiology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands; (N.O.); (S.K.M.); (I.C.A.); (T.J.D.); (E.J.S.); (P.J.B.)
| | - Kai Dallmeier
- Laboratory of Virology and Chemotherapy, Molecular Vaccinology and Vaccine Discovery, Department of Microbiology, Immunology and Transplantation, Rega Institute, KU Leuven, Herestraat 49 Box 1043, 3000 Leuven, Belgium; (N.M.); (K.D.)
| | - Marjolein Kikkert
- Center of Infectious Diseases LU-CID, Department of Medical Microbiology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands; (N.O.); (S.K.M.); (I.C.A.); (T.J.D.); (E.J.S.); (P.J.B.)
| |
Collapse
|
7
|
Rodríguez-Morales AJ, Bonilla-Aldana DK, Suárez JA, Franco-Paredes C, Forero-Peña DA, Mattar S, Villamil-Gómez WE, Ruíz-Sáenz J, Cardona-Ospina JA, Figuera ME, Sierra-Carrero LL, Risquez A, Cimerman S, Valero-Cedeño N, Cabrera M, Robaina-Barrios AJ, López-Díaz L, Barbella R, Navas RM, Díaz-Quijano F, Carrero Y, Pineda A, Brito MO, Savio-Larriera E, Martinez-Gutierrez M, Maquera-Afaray J, Solarte-Portilla MA, Hernández-Botero S, Contreras K, López MG, Henao-Martinez AF, Ortiz-Martinez Y, Chaves TDSS, Orduna T, Lepetic A, Macchi A, Verbanaz S, Perret C, Echazarreta S, Lloveras SC, Gallego V, Navarro JC, Paniz-Mondolfi A. Yellow fever reemergence in Venezuela - Implications for international travelers and Latin American countries during the COVID-19 pandemic. Travel Med Infect Dis 2021; 44:102192. [PMID: 34751150 PMCID: PMC8553654 DOI: 10.1016/j.tmaid.2021.102192] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2021] [Accepted: 10/26/2021] [Indexed: 11/16/2022]
Affiliation(s)
- Alfonso J Rodríguez-Morales
- Grupo de Investigación Biomedicina, Faculty of Medicine, Fundación Universitaria Autónoma de las Américas, Pereira, Risaralda, Colombia; Committe on Tropical Medicine, Zoonoses and Travel Medicine, Colombian Association of Infectious Diseases (ACIN), Bogota, Colombia; Semillero de Zoonosis, Grupo de Investigación GISCA, Fundación Universitaria Autónoma de las Américas, Sede Pereira, Pereira, Risaralda, Colombia; Emerging Infectious Diseases and Tropical Medicine Research Group, Instituto para la Investigación en Ciencias Biomédicas - Sci-Help, Pereira, Risaralda, Colombia; Committe on Travel Medicine, Pan-American Association of Infectious Diseases (API), Panama City, Panama; Master of Clinical Epidemiology and Biostatistics, Universidad Cientifica del Sur, Lima, Peru; Grupo de Investigación Biomedicina, Faculty of Medicine, Institución Universitaria Visión de las Américas, Pereira, Risaralda, Colombia.
| | - D Katterine Bonilla-Aldana
- Committe on Tropical Medicine, Zoonoses and Travel Medicine, Colombian Association of Infectious Diseases (ACIN), Bogota, Colombia; Semillero de Zoonosis, Grupo de Investigación GISCA, Fundación Universitaria Autónoma de las Américas, Sede Pereira, Pereira, Risaralda, Colombia; Emerging Infectious Diseases and Tropical Medicine Research Group, Instituto para la Investigación en Ciencias Biomédicas - Sci-Help, Pereira, Risaralda, Colombia; Semillero de Zoonosis, Grupo de Investigación GISCA, Institución Universitaria Visión de las Américas, Sede Pereira, Pereira, Risaralda, Colombia
| | - José Antonio Suárez
- Committe on Travel Medicine, Pan-American Association of Infectious Diseases (API), Panama City, Panama; Investigador SNI Senacyt Panamá, Clinical Research Deparment, Instituto Conmemorativo Gorgas de Estudios de la Salud, Panama City, Panama
| | - Carlos Franco-Paredes
- Committe on Travel Medicine, Pan-American Association of Infectious Diseases (API), Panama City, Panama; Division of Infectious Diseases, Department of Medicine, University of Colorado Anschutz Medical Center, Aurora, CO, USA; Hospital Infantil de México, Federico Gómez, México City, Mexico
| | - David A Forero-Peña
- Biomedical Research and Therapeutic Vaccines Institute, Ciudad Bolivar, Venezuela
| | - Salim Mattar
- Committe on Tropical Medicine, Zoonoses and Travel Medicine, Colombian Association of Infectious Diseases (ACIN), Bogota, Colombia; Instituto de Investigaciones Biológicas del Trópico, Universidad de Córdoba, Colombia
| | - Wilmer E Villamil-Gómez
- Committe on Tropical Medicine, Zoonoses and Travel Medicine, Colombian Association of Infectious Diseases (ACIN), Bogota, Colombia; Committe on Travel Medicine, Pan-American Association of Infectious Diseases (API), Panama City, Panama; Infectious Diseases and Infection Control Research Group, Hospital Universitario de Sincelejo, Sincelejo, Sucre, Colombia; Programa del Doctorado de Medicina Tropical, SUE Caribe, Universidad del Atlántico, Barranquilla, Colombia
| | - Julián Ruíz-Sáenz
- Committe on Tropical Medicine, Zoonoses and Travel Medicine, Colombian Association of Infectious Diseases (ACIN), Bogota, Colombia; Grupo de Investigación en Ciencias Animales, Universidad Cooperativa de Colombia, Bucaramanga, Colombia
| | - Jaime A Cardona-Ospina
- Grupo de Investigación Biomedicina, Faculty of Medicine, Fundación Universitaria Autónoma de las Américas, Pereira, Risaralda, Colombia; Committe on Tropical Medicine, Zoonoses and Travel Medicine, Colombian Association of Infectious Diseases (ACIN), Bogota, Colombia; Emerging Infectious Diseases and Tropical Medicine Research Group, Instituto para la Investigación en Ciencias Biomédicas - Sci-Help, Pereira, Risaralda, Colombia; Committe on Travel Medicine, Pan-American Association of Infectious Diseases (API), Panama City, Panama; Semillero de Investigación en Infecciones Emergentes y Medicina Tropical, Faculty of Medicine, Fundación Universitaria Autónoma de las Américas, Pereira, Risaralda, Colombia; Grupo de Investigación Biomedicina, Faculty of Medicine, Institución Universitaria Visión de las Américas, Pereira, Risaralda, Colombia
| | | | - Leandro Luis Sierra-Carrero
- Department of Medicine, Health Sciences Division, Universidad del Norte and Hospital Universidad del Norte, Barranquilla, Colombia
| | - Alejandro Risquez
- Committe on Travel Medicine, Pan-American Association of Infectious Diseases (API), Panama City, Panama; Faculty of Medicine, Universidad Central de Venezuela, Caracas, Venezuela
| | - Sergio Cimerman
- Institute of Infectious Diseases Emilio Ribas, São Paulo, Brazil
| | - Nereida Valero-Cedeño
- Carrera de Laboratorio Clínico, Universidad Estatal del Sur de Manabí, Cantón Jipijapa, Ecuador
| | - Maritza Cabrera
- Vicerrectoría de Investigación y Postgrado (VRIP), Universidad Católica del Maule, Chile
| | - Andrea J Robaina-Barrios
- Cardiology Division, Department of Internal Medicine, Hospital Universitario de Caracas, Faculty of Medicine, Universidad Central de Venezuela, Caracas, Venezuela
| | | | - Rosa Barbella
- Servicio de Anatomía Patológica, Complejo Hospitalario Universitario de Albacete, Facultad de Medicina, Universidad Castilla La Mancha, Albacete, Spain
| | - Rosa M Navas
- Health Care Service, International Airport Camilo Daza, Cúcuta, Norte de Santander, Colombia
| | - Fredi Díaz-Quijano
- Departamento de Epidemiologia, Faculdade de Saúde Pública da Universidade de São Paulo, São Paulo, SP, Brazil
| | | | | | - Maximo O Brito
- Division of Infectious Diseases, Department of Internal Medicine, University of Illinois, Chicago, IL, USA
| | | | - Marlen Martinez-Gutierrez
- Grupo de Investigación en Ciencias Animales-GRICA, Universidad Cooperativa de Colombia, Calle 30A #, 33-51, Bucaramanga, Colombia
| | - Julio Maquera-Afaray
- Infectious Diseases Division, Instituto Nacional de Salud del Niño San Borja, Lima, Peru; Facultad de Ciencias de la Salud, Universidad Privada de Tacna, Tacna, Peru
| | | | - Sebastián Hernández-Botero
- Coordination of Microbiology, School of Medicine, Universidad de Manizales, Manizales, Caldas, Colombia; Grupo de Resistencia Antibiótica de Manizales (GRAM), Manizales, Caldas, Colombia
| | - Krisell Contreras
- Clínica San José, Cúcuta, Norte de Santander, Colombia; Hospital Universitario Erasmo Meoz, Cúcuta, Norte de Santander, Colombia
| | - Maria Graciela López
- Division of Infectious Diseases, Hospital de Niños J. M. de Los Ríos, Caracas, Venezuela; Executive Board, Venezuelan Society of Infectious Diseases, Caracas, Venezuela
| | - Andrés F Henao-Martinez
- Division of Infectious Diseases, Department of Medicine, University of Colorado Anschutz Medical Center, Aurora, CO, USA
| | - Yeimer Ortiz-Martinez
- Department of Internal Medicine, Universidad Industrial de Santander, Bucaramanga, Santander, Colombia
| | - Tânia do Socorro Souza Chaves
- Evandro Chagas Institute, Health of Ministry of Brazil, Belém, Pará, Brazil; Faculdade de Medicina da Universidade Federal do Pará, Brazil
| | - Tomas Orduna
- Hospital de Infecciosas F. Muñíz, Buenos Aires, Argentina
| | - Alejandro Lepetic
- Clinical Research & Development and Medical Affairs for GSK Vaccines, Rio de Janeiro, 22783-110, Brazil
| | - Alejandra Macchi
- Hospital de Trauma y Emergencias Federico Abete, Buenos Aires, Argentina
| | | | - Cecilia Perret
- Department of Pediatric Infectious Diseases and Immunology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago de Chile, Chile
| | | | - Susana Cristina Lloveras
- Hospital de Infecciosas F. Muñíz, Buenos Aires, Argentina; Universidad de Buenos Aires, Buenos Aires, Argentina
| | - Viviana Gallego
- Panel of Sports and Travel, Latin American Society for Travel Medicine (SLAMVI), Buenos Aires, Argentina
| | - Juan-Carlos Navarro
- Research Group of Emerging Diseases, Ecoepidemiology and Biodiversity, Health Sciences Faculty, Universidad Internacional SEK, Quito, Ecuador; Instituto de Zoología y Ecología Tropical, Facultad de Ciencias, Universidad Central de Venezuela, Caracas, Venezuela
| | - Alberto Paniz-Mondolfi
- Committe on Travel Medicine, Pan-American Association of Infectious Diseases (API), Panama City, Panama; Department of Infectious Diseases and Tropical Medicine, Clínica IDB Cabudare, Instituto de Investigaciones Biomédicas IDB, Barquisimeto, 3023, Lara, Venezuela; Infectious Diseases Research Branch, Venezuelan Science Incubator and the Zoonosis and Emerging Pathogens Regional Collaborative Network, Cabudare, 3023, Lara, Venezuela; Laboratorio de Señalización Celular y Bioquímica de Parásitos, Instituto de Estudios Avanzados (IDEA), Caracas, Caracas, Venezuela; Academia Nacional de Medicina, Caracas, Venezuela; Direction of Microbiology, Department of Pathology, Molecular and Cell-based Medicine, The Mount Sinai Hospital-Icahn School of Medicine at Mount Sinai, New York, USA
| |
Collapse
|
8
|
Yellow Fever in Transplantation. Curr Infect Dis Rep 2021. [DOI: 10.1007/s11908-021-00761-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
9
|
Reno E, Quan NG, Franco-Paredes C, Chastain DB, Chauhan L, Rodriguez-Morales AJ, Henao-Martínez AF. Prevention of yellow fever in travellers: an update. THE LANCET. INFECTIOUS DISEASES 2020; 20:e129-e137. [PMID: 32386609 DOI: 10.1016/s1473-3099(20)30170-5] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/05/2019] [Revised: 02/28/2020] [Accepted: 03/02/2020] [Indexed: 12/20/2022]
Abstract
For centuries, yellow fever virus infection generated substantial fear among explorers, tourist travellers, workers, military personnel, and others entering areas of transmission. Currently, there is transmission only in some areas of tropical South America and sub-Saharan Africa. When symptomatic, yellow fever infection causes severe liver dysfunction and coagulopathy with elevated mortality rates. Since there is no effective treatment, vaccination against yellow fever, available since 1937, represents an important preventive intervention in endemic areas. Every year, an increasing number of individuals are travelling to yellow fever endemic areas, many of whom have complex medical conditions. Travel health practitioners should do individualised assessments of the risks and benefits of yellow fever vaccination to identify potential contraindications. The most relevant contraindications include a history of thymoma or thymus dysfunction, AIDS, and individuals receiving immunosuppressive drugs including biological therapies or chemotherapy. We briefly review strategies to prevent yellow fever infection in travellers with the use of yellow fever vaccination and the use of personal protection measures to avoid mosquito bites.
Collapse
Affiliation(s)
- Elaine Reno
- Department of Emergency Medicine, University of Colorado Denver, School of Medicine, Aurora, CO, USA
| | - Nicolas G Quan
- Department of Medicine, Division of Infectious Diseases, University of Colorado Denver, School of Medicine, Aurora, CO, USA
| | - Carlos Franco-Paredes
- Department of Medicine, Division of Infectious Diseases, University of Colorado Denver, School of Medicine, Aurora, CO, USA; Instituto Nacional de Salud, Hospital Infantil de México, Federico Gómez, Mexico City, Mexico
| | - Daniel B Chastain
- Department of Clinical and Administrative Pharmacy, University of Georgia College of Pharmacy, Albany, GA, USA
| | - Lakshmi Chauhan
- Department of Medicine, Division of Infectious Diseases, University of Colorado Denver, School of Medicine, Aurora, CO, USA
| | - Alfonso J Rodriguez-Morales
- Public Health and Infection Research Group, Faculty of Health Sciences, Universidad Tecnológica de Pereira, Pereira, Colombia; Grupo de Investigación Biomedicina, Faculty of Medicine, Fundación Universitaria Autónoma de las Américas, Pereira, Colombia.
| | - Andrés F Henao-Martínez
- Department of Medicine, Division of Infectious Diseases, University of Colorado Denver, School of Medicine, Aurora, CO, USA
| |
Collapse
|
10
|
Domingo C, Fraissinet J, Ansah PO, Kelly C, Bhat N, Sow SO, Mejía JE. Long-term immunity against yellow fever in children vaccinated during infancy: a longitudinal cohort study. THE LANCET. INFECTIOUS DISEASES 2019; 19:1363-1370. [PMID: 31543249 PMCID: PMC6892259 DOI: 10.1016/s1473-3099(19)30323-8] [Citation(s) in RCA: 30] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 02/28/2019] [Revised: 05/24/2019] [Accepted: 06/07/2019] [Indexed: 12/15/2022]
Abstract
BACKGROUND A single dose of vaccine against yellow fever is routinely administered to infants aged 9-12 months under the Expanded Programme on Immunization, but the long-term outcome of vaccination in this age group is unknown. We aimed to evaluate the long-term persistence of neutralising antibodies to yellow fever virus following routine vaccination in infancy. METHODS We did a longitudinal cohort study, using a microneutralisation assay to measure protective antibodies against yellow fever in Malian and Ghanaian children vaccinated around age 9 months and followed up for 4·5 years (Mali), or 2·3 and 6·0 years (Ghana). Healthy children with available day-0 sera, a complete follow-up history, and no record of yellow fever revaccination were included; children seropositive for yellow fever at baseline were excluded. We standardised antibody concentrations with reference to the yellow fever WHO International Standard. FINDINGS We included 587 Malian and 436 Ghanaian children vaccinated between June 5, 2009, and Dec 26, 2012. In the Malian group, 296 (50·4%, 95% CI 46·4-54·5) were seropositive (antibody concentration ≥0·5 IU/mL) 4·5 years after vaccination. Among the Ghanaian children, 121 (27·8%, 23·5-32·0) were seropositive after 2·3 years. These results show a large decrease from the proportions of seropositive infants 28 days after vaccination, 96·7% in Mali and 72·7% in Ghana, reported by a previous study of both study populations. The number of seropositive children increased to 188 (43·1%, 95% CI 38·5-47·8) in the Ghanaian group 6·0 years after vaccination, but this result might be confounded by unrecorded revaccination or natural infection with wild yellow fever virus during a 2011-12 outbreak in northern Ghana. INTERPRETATION Rapid waning of immunity during the early years after vaccination of 9-month-old infants argues for a revision of the single-dose recommendation for this target population in endemic countries. The short duration of immunity in many vaccinees suggests that booster vaccination is necessary to meet the 80% population immunity threshold for prevention of yellow fever outbreaks. FUNDING Wellcome Trust.
Collapse
Affiliation(s)
- Cristina Domingo
- Robert Koch Institute, Highly Pathogenic Viruses (ZBS 1), Centre for Biological Threats and Special Pathogens, WHO Collaborating Centre for Emerging Infections and Biological Threats, Berlin, Germany.
| | - Juliane Fraissinet
- Robert Koch Institute, Highly Pathogenic Viruses (ZBS 1), Centre for Biological Threats and Special Pathogens, WHO Collaborating Centre for Emerging Infections and Biological Threats, Berlin, Germany
| | - Patrick O Ansah
- Navrongo Health Research Centre and Research Laboratory, Navrongo, Ghana
| | | | | | - Samba O Sow
- National Institute of Research on Public Health, Bamako, Mali
| | - José E Mejía
- Centre de Physiopathologie Toulouse-Purpan (CNRS, INSERM, Université Paul Sabatier), Centre Hospitalier Universitaire Purpan, Toulouse, France
| |
Collapse
|
11
|
Makhani L, Khatib A, Corbeil A, Kariyawasam R, Raheel H, Clarke S, Challa P, Hagopian E, Chakrabarti S, Schwartz KL, Boggild AK. 2018 in review: five hot topics in tropical medicine. Trop Dis Travel Med Vaccines 2019; 5:5. [PMID: 31016025 PMCID: PMC6466725 DOI: 10.1186/s40794-019-0082-z] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2019] [Accepted: 03/28/2019] [Indexed: 02/07/2023] Open
Abstract
The year 2018 heralded many new developments in the field of tropical medicine, including licensure of novel drugs for novel indications, licensure of existing drugs for existing indications but in novel settings, and globalized outbreaks of both vector-borne and zoonotic diseases. We herein describe five top stories in tropical medicine that occurred during 2018, and illuminate the practice-changing development within each story.
Collapse
Affiliation(s)
- Leila Makhani
- Department of Family and Community Medicine, University of Toronto, Toronto, Canada
- Tropical Disease Unit, Toronto General Hospital, 200 Elizabeth Street, 13EN-218, Toronto, ON M5G 2C4 Canada
| | - Aisha Khatib
- Department of Family and Community Medicine, University of Toronto, Toronto, Canada
- Tropical Disease Unit, Toronto General Hospital, 200 Elizabeth Street, 13EN-218, Toronto, ON M5G 2C4 Canada
| | - Antoine Corbeil
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada
| | | | - Hira Raheel
- Faculty of Medicine, University of Toronto, Toronto, Canada
| | - Shareese Clarke
- Tropical Disease Unit, Toronto General Hospital, 200 Elizabeth Street, 13EN-218, Toronto, ON M5G 2C4 Canada
| | - Priyanka Challa
- Department of Life Science, University of Toronto, Toronto, Canada
| | - Emma Hagopian
- Department of Arts and Science, University of Toronto, Toronto, Canada
| | - Sumontra Chakrabarti
- Tropical Disease Unit, Toronto General Hospital, 200 Elizabeth Street, 13EN-218, Toronto, ON M5G 2C4 Canada
- Department of Medicine, University of Toronto, Toronto, Canada
- Division of Infectious Diseases, Trillium Health Partners, Mississauga, Canada
| | - Kevin L. Schwartz
- Tropical Disease Unit, Toronto General Hospital, 200 Elizabeth Street, 13EN-218, Toronto, ON M5G 2C4 Canada
- Division of Infectious Diseases, St. Joseph’s Health Centre, Toronto, Canada
- Dalla Lana School of Public Health, University of Toronto, Toronto, Canada
- Public Health Ontario, Toronto, Canada
| | - Andrea K. Boggild
- Tropical Disease Unit, Toronto General Hospital, 200 Elizabeth Street, 13EN-218, Toronto, ON M5G 2C4 Canada
- Institute of Medical Science, University of Toronto, Toronto, Canada
- Department of Medicine, University of Toronto, Toronto, Canada
- Public Health Ontario, Toronto, Canada
| |
Collapse
|
12
|
Selemane I. Epidemiological monitoring of the last outbreak of yellow fever in Brazil - An outlook from Portugal. Travel Med Infect Dis 2018; 28:46-51. [PMID: 30583006 DOI: 10.1016/j.tmaid.2018.12.008] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2017] [Revised: 03/24/2018] [Accepted: 12/20/2018] [Indexed: 10/27/2022]
Abstract
BACKGROUND Yellow Fever (YF) is a high fatality rate disease (30-50%) caused by Flavivirus, present in some African and South American countries. In order to determine the magnitude and epidemiological distribution of YF cases, vaccination coverage and most affected regions in Brazil, a descriptive epidemiological study monitoring the last outbreak was undertaken in Portugal. METHOD The Brazilian database "Portal da Saude" was used to collect data on cases of YF. We used Microsoft Excel on a weekly basis to update the suspected, confirmed and mortality cases as well as the case fatality rate and epizootics in non-human primates. RESULTS Case Fatality Rate was 33.6%. A total and 82% of confirmed cases were males. The outbreak predominantly affected two south-eastern states, Minas Gerais and Espírito Santo, both with a very low vaccination coverage. CONCLUSIONS The last outbreak of YF was by far the largest observed over the last few decades! Until the emergence of this outbreak, Espírito Santo, Bahia and Rio de Janeiro were states of low risk for YF and the vaccine not previously recommended. The World Health Organization's "Global Strategy to Eliminate Yellow Fever Epidemic" (EYE) should be on the way, to prevent YF outbreaks in Brazil and other countries in Africa and South America.
Collapse
Affiliation(s)
- Ismael Selemane
- Unidade Local de Saúde do Litoral Alentejano (ULSLA), Portugal.
| |
Collapse
|
13
|
Towards the risk of yellow fever transmission in Europe. Clin Microbiol Infect 2018; 25:10-12. [PMID: 30170135 DOI: 10.1016/j.cmi.2018.08.015] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2018] [Revised: 08/18/2018] [Accepted: 08/19/2018] [Indexed: 11/22/2022]
|
14
|
Chaves TDSS, Orduna T, Lepetic A, Macchi A, Verbanaz S, Risquez A, Perret C, Echazarreta S, Rodríguez-Morales AJ, Lloveras SC. Yellow fever in Brazil: Epidemiological aspects and implications for travelers. Travel Med Infect Dis 2018; 23:1-3. [PMID: 29751132 DOI: 10.1016/j.tmaid.2018.05.001] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2018] [Revised: 04/30/2018] [Accepted: 05/03/2018] [Indexed: 11/17/2022]
Affiliation(s)
- Tânia do Socorro Souza Chaves
- Evandro Chagas Institute, Health of Ministry of Brazil, Rodovia BR 316 Km 07, S/N, CEP 67030-000 Ananindeua, Pará, Brazil; Faculdade de Medicina da Universidade Federal do Pará, Brazil.
| | - Tomas Orduna
- Hospital de Infecciosas F. Muñíz, Buenos Aires, Argentina
| | - Alejandro Lepetic
- Scientific Affairs and Public Health Medical Director for GSK Vaccines in Latin America, Buenos Aires, Argentina
| | - Alejandra Macchi
- Hospital de Trauma y Emergencias, Federico Abete, Buenos Aires, Argentina
| | | | - Alejandro Risquez
- Faculty of Medicine, Universidad Central de Venezuela, Caracas, Venezuela
| | - Cecilia Perret
- Department of Pediatric Infectious Diseases and Immunology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago de Chile, Chile
| | | | - Alfonso J Rodríguez-Morales
- Associate Editor, Travel Medicine and Infectious Diseases, Public Health and Infection Research Group, Faculty of Health Sciences Universidad Tecnológica de Pereira, Pereira, Risaralda, Colombia; Medical School, Faculty of Health Sciences, UniFranz, Cochabamba, Bolivia.
| | - Susana Cristina Lloveras
- Hospital de Infecciosas F. Muñíz, Buenos Aires, Argentina; Editorial Board, Travel Medicine and Infectious Diseases, Universidad de Buenos Aires, Buenos Aires, Argentina
| |
Collapse
|
15
|
Affiliation(s)
- Helio Arthur Bacha
- Hospital Israelita Albert Einstein, Brazil; Sociedade Brasileira de Infectologia, Brazil; Universidade de São Paulo, Brazil; American College of Physicians, United States
| | - Gustavo Henrique Johanson
- Hospital Israelita Albert Einstein, Brazil; University of London, United Kingdom; Royal College of Physicians of London, United Kingdom; International Society of Travel Medicine, United States
| |
Collapse
|
16
|
Ortiz-Martínez Y, Patiño-Barbosa AM, Rodriguez-Morales AJ. Yellow fever in the Americas: the growing concern about new epidemics. F1000Res 2017; 6:398. [PMID: 28529708 PMCID: PMC5414809 DOI: 10.12688/f1000research.11280.2] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 04/24/2017] [Indexed: 12/04/2022] Open
Abstract
Yellow fever (YF) is a haemorrhagic viral disease with a high case fatality rate. It is considered a reemerging infectious disease of remarkable importance. During the last outbreaks in Brazil (2016-2017), many cases of YF emerged despite high YF vaccination coverage in some areas. However, there are many areas and populations worldwide where vaccination coverage has been low for years (e.g. Nigeria), which increases the risk of major epidemics in such areas, as would be the case in many of the American territories. Several factors, including the vast border and migratory status of Brazil, the widespread distribution of
Aedes mosquitoes and the lack of efficient health policies and surveillance systems, favor this complex epidemiological scenario of reemergence. Therefore, mass vaccination of the population at risk, public health awareness and preparedness are urgently needed in this region. This opinion article describes the current global epidemiological situation of YF, focusing especially on the Americas, as well the risk and vulnerabilities in the region that would be of concern for major expansion to other countries apart from Brazil. Also, imported risk from endemic area outside of Americas (i.e. Africa) are of current concern.
Collapse
Affiliation(s)
| | - Andrés Mauricio Patiño-Barbosa
- Public Health and Infection Research Group, Faculty of Health Sciences, Universidad Tecnológica de Pereira, Pereira, Risaralda, Colombia
| | - Alfonso J Rodriguez-Morales
- Public Health and Infection Research Group, Faculty of Health Sciences, Universidad Tecnológica de Pereira, Pereira, Risaralda, Colombia.,Colombian Collaborative Network on Zika and other Arboviruses (RECOLZIKA), Pereira, Risaralda, Colombia
| |
Collapse
|
17
|
Schlagenhauf-Lawlor P, Poumerol G, Santos-O'Connor F. Microbes on the move: prevention, required vaccinations, curtailment, outbreak. Infect Dis (Lond) 2017. [DOI: 10.1002/9781119085751.ch5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/08/2022] Open
Affiliation(s)
- Patricia Schlagenhauf-Lawlor
- University of Zürich; WHO Collaborating Centre for Travellers’ Health, Epidemiology, Biostatistics and Prevention Institute; Zürich Switzerland
| | - Giles Poumerol
- World Health Organization; International Health Regulations Department; Geneva Switzerland
| | - Francisco Santos-O'Connor
- Labour Administration, Labour Inspection and Occupational Safety and Health Branch; International Labour Office; Geneva Switzerland
| |
Collapse
|